[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100485229":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":25,"responsibleParty":43,"collaborators":46,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":25,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":25,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":25,"overallStatus":72,"whyStopped":25,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":25},{"fullName":5,"class":6},"Medical College of Wisconsin","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TA-65","EXPERIMENTAL","TA-65 (250 U) taken once per day",[13],"Dietary Supplement: TA-65",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo taken once per day",[19],"Other: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","TA-65 is a purified small molecule extracted from Astragalus root",[9],null,{"type":6,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Inactive formulation",[15],[30],{"name":31,"affiliation":32,"role":33},"Andreas Beyer, Ph.D.","Associate Professor","PRINCIPAL_INVESTIGATOR",[35,39],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","414-955-7514","abeyer@mcw.edu",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":42},"William Hughes, Ph.D.","414-955-7519","whughes@mcw.edu",{"type":33,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"William Hughes","Postdoc Fellow",[47,49],{"name":48,"class":6},"University of Louisville",{"name":50,"class":6},"Penn State University","100485229","ta-65-and-aging-associated-microvascular-dysfunction-100485229",false,"NCT05598359","TA-65 and Aging Associated Microvascular Dysfunction","Inclusion Criteria:\n\n* Healthy Adults 18 - 35 and 65+ years of age\n* Subjects with clinical diagnosis of CAD\n\nExclusion criteria will include:\n\n* 36-64 years of age without clinical diagnosis of CAD\n* Self-reported habitual vigorous exercise (\\>20 min, 3 times per week, 1 yr)\n* Major Adverse Cardiovascular Event (MACE) in the last year (heart attack, stroke)\n* Heart Failure\n* Renal Impairment\n* \\>3 Pre-existing Cardiovascular Risk Factors (healthy groups only)\n* Type 1 or type 2 diabetes\n* Uncontrolled hypertension\n* Current tobacco use or within last 6 months\n* BMI \\> 35\n* Hyperlipidemia\n* Hypercholesterolemia\n* Use of anti-coagulant drugs\n* Use of anti-platelet drugs\n* Erectile dysfunction medication in the past 6 months\n* Use of topical\u002Fnon-topical steroids in last 6 months\n* Hormone replacement therapy (Post-Menopause or Gender Reassignment)\n* History of retinopathy\n* Documented neuromuscular disorders\n* Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)\n* Pregnancy (young female subjects)\n* Allergy to lidocaine\n* Current diagnosis of cancer with or without active anti-cancer treatment (pharmaceuticals) or treatment within last 12 months\n* Active COVID-19 or within the past 3 months",true,"ALL","18 Years","80 Years",{"count":62,"type":63},180,"ESTIMATED","INTERVENTIONAL",[66],"NA","The goal of this clinical trial is to test whether activation of telomerase with a dietary supplement (TA-65) improves microvascular function.",[69,70,71],"Telomere Shortening","Aging","Vascular Diseases","NOT_YET_RECRUITING","2026-04-27",{"date":75,"type":76},"2026-05-01","ACTUAL",{"date":78,"type":63},"2027-01-01",{"date":80,"type":63},"2029-12-31",{"name":5,"class":6}]